

Literaturverzeichnis zum Titelthema „Entzündlich rheumatische Erkrankungen heute“

von Dr. Vanessa Bartsch und Professor Dr. Dr. Axel J. Hueber

Bayerisches Ärzteblatt 3/2026, Seite 64 ff.

1. Albrecht K, Binder S, Minden K, Poddubnyy D, Regierer AC, Strangfeld A, et al. Systematisches Review zur Schätzung der Prävalenz entzündlich rheumatischer Erkrankungen in Deutschland. *Z Rheumatol.* 2023 Nov 2;82(9):727–38.
2. Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, et al. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. *Rheumatology.* 2019 Dec 1;58(12):2284–94.
3. Sapundzhieva T, Sapundzhiev L, Batalov A. Practical Use of Ultrasound in Modern Rheumatology—From A to Z. 2024 Sep 23;14(9):1208.
4. Müller F, Hagen M, Wirsching A, Kharboutli S, Aigner M, Völkl S, et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. *Nat Med.* 2026 Jan 7;
5. Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Med.* 2022 Oct 15;28(10):2124–32.
6. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis.* 2023 Jan;82(1):3–18.
7. Thiele K, Albrecht K, Alexander T, Aringer M, Detert J, Eidner T, et al. Kerndokumentation der regionalen kooperativen Rheumazentren - Versorgungstrends 2025. 2025.
8. Sugihara T, Tanaka E, Matsui T. Low-Dose Glucocorticoids in Older Patients with Rheumatoid Arthritis: What Does the Evidence Say? *Drugs Aging.* 2024 Aug 27;41(8):641–52.
9. Almayali AAH, Boers M, Hartman L, Opris D, Bos R, Kok MR, et al. Three-month tapering and discontinuation of long-term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. *Ann Rheum Dis.* 2023 Oct;82(10):1307–14.
10. Sakai R, Tanaka E, Majima M, Harigai M. Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study. *Arthritis Res Ther.* 2022 Dec 10;24(1):135.
11. Freitas R, Godinho F, Madeira N, Fernandes BM, Costa F, Santiago M, et al. Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study. *Drugs Aging.* 2020 Dec 18;37(12):899–907.
12. Burg LC, Karakostas P, Behning C, Brossart P, Kermani TA, Schäfer VS. Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study. *Ther Adv Musculoskelet Dis.* 2023 Jan 7;15.
13. Nielsen AW, Frølund LL, Våben C, Bonde AR, Gormsen LC, de Thurah AL, et al. Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica – A systematic review and meta-analysis. *Semin Arthritis Rheum.* 2022 Oct;56:152069.
14. Dejaco C, Ramiro S, Bond M, Bosch P, Ponte C, Mackie SL, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. *Ann Rheum Dis.* 2024 Jun;83(6):741–51.
15. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in Giant-Cell Arteritis. *New England Journal of Medicine.* 2017 Jul 27;377(4):317–28.
16. Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. *New England Journal of Medicine.* 2025 May 29;392(20):2013–24.

17. Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, et al. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. *New England Journal of Medicine*. 2023 Oct 5;389(14):1263–72.
18. Buttgereit F, Boyadzhieva Z, Reisch M, Schneider M, Brabant T, Daikeler T, et al. S2e-Leitlinie zur Behandlung der Polymyalgia rheumatica: Update 2024. 2024.
19. Nakajima A, Inoue E, Shimizu Y, Kobayashi A, Shidara K, Sugimoto N, et al. Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. *Clin Rheumatol*. 2015 Mar 31;34(3):441–9.
20. Fatima S, Pope JE, Chen LR, Schieir O, Valois MF, Bartlett SJ, et al. Higher comorbidities associated with less improvement in disease activity in early rheumatoid arthritis: results from CATCH cohort. *Rheumatology*. 2025 Jun 25;
21. Baillet A, Gossec L, Carmona L, Wit M de, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. *Ann Rheum Dis*. 2016 Jun;75(6):965–73.
22. Nikiphorou E, de Lusignan S, Mallen CD, Khavandi K, Bedarida G, Buckley CD, et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. *Heart*. 2020 Oct;106(20):1566–72.
23. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DPM. Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. *Arthritis Rheum*. 2002 Aug 9;46(8):2010–9.
24. Crowson CS, Rollefstad S, Ikeda E, Kitas GD, van Riel PLCM, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2018 Jan;77(1):48–54.
25. Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. *RMD Open*. 2019 Jun 9;5(1):e000935.
26. Wagner N, Assmus F, Arendt G, Baum E, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Vol. 62, *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz*. NLM (Medline); 2019. p. 494–515.
27. Kommission „Impfungen und Infektionen bei rheumatischen Erkrankungen“. Impfen bei entzündlich-rheumatischen Erkrankungen. Empfehlungen der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie e.V. 2025/2026 [Internet]. 2025 [cited 2026 Jan 11]. Available from: <https://dgrh.de/Aktuelles/Impfungen-bei-entz%C3%BCndlich-rheumatischen-Erkrankungen.html>
28. Goulenok T, Carvalho M, Mageau A, Terrier B, Hachulla E, Papo T, et al. Varicella Zoster Virus Vaccination in Patients With Immune-Mediated Inflammatory Diseases: Drivers and Barriers. *J Rheumatol*. 2025 Jun 1;jrheum.2025-0016.
29. Jeon KH, Han K, Jung J, Park C II, Eun Y, Shin DW, et al. Rheumatoid Arthritis and Risk of Depression in South Korea. *JAMA Netw Open*. 2024 Mar 5;7(3):e241139.
30. Reich A, Weiß A, Lindner L, Zinke S, Stille C, Detert J, et al. Effect of depressive symptoms on treatment response in patients with axSpA: data from the RABBIT-SpA register. *RMD Open*. 2025 Apr 8;11(2):e005422.
31. Bartsch V, Knitza J. Digitale Gesundheitsanwendungen. *Z Rheumatol*. 2025 Dec 20;84(10):798–804.